John J. Sperzel III files SEC Form 4 disclosures for T2 Biosystems, Inc.. They have made 1 open-market trade across 1 company since 2022, most recently 2024-02-24.
CIK 0001602618
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $15K since 2022, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.